Furthermore, CQ appears to be therapeutically useful for both gefitinib-sensitive and -resistant NSCLC, suggesting that CQ and its analogs may be a promising cancer therapy [38–39] for lung cancer patients with EGFR mutation who develop an acquired resistance after receiving gefitinib treatment. Here, EGFR is linked to non-small cell lung carcinoma.